Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sakshi Yadav

Internal Medicine Reno, NV Medical Doctor

NPI 1831751957 CMS profile 7165197

5437 Kietzke Ln, Reno, NV 89511

Open in the dashboard

General payments

$1,126

37 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sakshi Yadav of Reno, NV is reported in the CMS Open Payments database as having received $1,126 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $528 26
2024 General $161 7
2023 General $437 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sakshi Yadav
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sakshi Yadav were reported at $528. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sakshi Yadav Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $437 $149 $45–$519 $160
2024 $161 $154 $47–$537 $164
2025 $528 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Calliditas Therapeutics US Inc. $230 13 payments
  2. GlaxoSmithKline, LLC. $200 2 payments
  3. AstraZeneca Pharmaceuticals LP $140 2 payments
  4. Alexion Pharmaceuticals, Inc. $117 1 payment
  5. Retrophin, Inc. $106 5 payments
  6. Otsuka America Pharmaceutical, Inc. $64 3 payments
  7. ANI Pharmaceuticals, Inc. $55 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $48 2 payments
  9. Abiomed $27 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $26 1 payment
  11. Other $112 5 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,126 37 payments
Products named General payments · program years 2023–2025
  1. TARPEYO Nephrology $197 11 payments
  2. FARXIGA $140 2 payments
  3. BENLYSTA $103 1 payment
  4. JESDUVROQ $97 1 payment
  5. PURIFIED CORTROPHIN GEL $55 2 payments
  6. JARDIANCE $48 2 payments
  7. JYNARQUE $42 2 payments
  8. TARPEYO Nephrology $34 2 payments
  9. Impella $27 1 payment
  10. Kerendia $26 1 payment
  11. Other $137 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

239

Median for Nephrology: 954

Drug cost

$26,791

Median for Nephrology: $127,050

Branded share of claims

22.2%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 33 $22,956
Sevelamer Carbonate Generic 17 $1,864
Nifedipine Er Nifedipine Brand 20 $512
Calcitriol Generic 30 $491
Torsemide Generic 22 $332
Losartan Potassium Generic 25 $241
Amlodipine Besylate Generic 32 $163
Furosemide Generic 16 $94
Spironolactone Generic 21 $76
Famotidine Generic 12 $31

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$45,573

Medicare's payments for the services billed

Medicare patients

239

Average age 73

Services billed

425

107 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 47%
Arthritis 44%
Heart failure 41%
Ischemic heart disease 38%
Atrial fibrillation 26%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $34
$34 — —
JYNARQUE
  • Otsuka America Pharmaceutical, Inc. $26
$26 — —
Velphoro
  • Fresenius USA Marketing, Inc. $22
$22 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$18 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record